Flex Pharma, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2014)
Status: Acquired by Salarius Pharmaceuticals, LLC (2019)

Organization Overview

First Clinical Trial
2017
NCT03196375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Flex Pharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Flex Pharma, Inc. (0) Acquired (2)

flx-787 (4 trials)

seclidemstat (4 trials)

Drugs in Phase 1 Trials (1)

Key: Flex Pharma, Inc. (0) Acquired (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Charcot-Marie-Tooth Disease (Phase 2)

Fasciculation (Phase 2)

Hereditary Sensory and Motor Neuropathy (Phase 2)

Motor Neuron Disease (Phase 2)

Muscle Cramp (Phase 2)

Nerve Compression Syndromes (Phase 2)

Sclerosis (Phase 2)

Spasm (Phase 2)

Tooth Diseases (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 8
  • # of Trial APIs: 3